SEC Form 4 · accession 0001737329-26-000016
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Iannone
Officer — EVP, Global Head of R&D & CMO
Period of report
Aug 27, 2026
Accepted (ET)
Aug 31, 2026 · 6:45 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Aug 27, 2026 | M | 26,116 | $113.10 | A | 111,223 | D | |
| Ordinary Shares | Aug 27, 2026 | M | 884 | $113.10 | A | 112,107 | D | |
| Ordinary Shares | Aug 27, 2026 | M | 27,584 | $137.12 | A | 139,691 | D | |
| Ordinary Shares | Aug 27, 2026 | M | 2,916 | $137.12 | A | 142,607 | D | |
| Ordinary SharesF2 | Aug 27, 2026 | S | 18,187 | $247.8573 | D | 124,420 | D | |
| Ordinary SharesF3 | Aug 27, 2026 | S | 11,423 | $248.6664 | D | 112,997 | D | |
| Ordinary SharesF4 | Aug 27, 2026 | S | 18,113 | $250.0178 | D | 94,884 | D | |
| Ordinary SharesF5 | Aug 27, 2026 | S | 19,639 | $250.6032 | D | 75,245 | D | |
| Ordinary SharesF6 | Aug 27, 2026 | S | 9,259 | $251.9499 | D | 65,986 | D | |
| Ordinary Shares | Aug 27, 2026 | S | 300 | $252.76 | D | 65,686 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F7 | $113.10 | Aug 27, 2026 | M | 884 | D | — | Feb 26, 2030 | Ordinary Shares | 884 | 0 | D |
| Incentive Stock Option (right to buy)F8 | $137.12 | Aug 27, 2026 | M | 2,916 | D | — | Aug 7, 2029 | Ordinary Shares | 2,916 | 0 | D |
| Non-Qualified Stock Option (right to buy)F7 | $113.10 | Aug 27, 2026 | M | 26,116 | D | — | Feb 26, 2030 | Ordinary Shares | 26,116 | 0 | D |
| Non-Qualified Stock Option (right to buy)F8 | $137.12 | Aug 27, 2026 | M | 27,584 | D | — | Aug 7, 2029 | Ordinary Shares | 27,584 | 0 | D |
Explanation of responses
- F1This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
- F2Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $247.29 to $248.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F3Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $248.29 to $249.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $249.33 to $250.325 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $250.33 to $251.29. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F6Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $251.37 to $252.31. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F7These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.
- F8These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter.